Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Hum Ecol Interdiscip J ; 51(2): 209-219, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37122818

RESUMEN

The Paiter Suruí people in the southwestern Brazilian Amazon have a complex food system that includes insects and crustaceans. We designed our study to systematize data about the invertebrates they incorporate into their traditional diet. After conducting a review of the literature, we verified and expanded the data through semi-structured interviews with Paiter Suruí volunteers, and traced trends in their consumption of invertebrates. We identified 61 invertebrates, including 58 insects of the orders Coleoptera, Lepidoptera, Hymenoptera, and three crustaceans. While beetle larvae remain a popular choice, consumption of other insects and crustaceans seems to have diminished over time.

2.
Acta Reumatol Port ; 36(4): 385-8, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-22472929

RESUMEN

The authors present the revised version of the Portuguese Society of Rheumatology (SPR) guidelines for the treatment of Rheumatoid Arthritis (RA) with biological therapies. In these guidelines the criteria for introduction and maintenance of biological agents are discussed as well as the contraindications and procedures in the case of nonresponders. Biological treatment (with a tumour necrosis factor antagonist, abatacept or tocilizumab) should be considered in RA patients with a disease activity score 28 (DAS 28) equal to or greater than 3.2 despite treatment with at least 20mg-weekly-dose of methotrexate (MTX) for at least 3 months or, if such treatment is not possible, after 3 months of other conventional disease modifying drug or combination therapy. A DAS 28 score between 2.6 and 3.2 with a significant functional or radiological deterioration under treatment with conventional regimens could also constitute an indication for biological treatment. The treatment goal should be remission or, if that is not achievable, at least a low disease activity, defined by a DAS28 lower than 3.2, without significative functional or radiological worsening. The response criteria, at the end of the first 3 months of treatment, are a decrease of at least 0.6 in the DAS28 score. After 6 months of treatment res­ponse criteria is defined as a decrease greater than 1.2 in the DAS28 score. Non-responders, in accordance to the Rheumatologist's clinical opinion, should try a switch to another biological agent (tumour necrosis factor antagonist, abatacept, rituximab or tocilizumab).


Asunto(s)
Artritis Reumatoide/tratamiento farmacológico , Productos Biológicos/uso terapéutico , Humanos , Portugal
3.
Acta Reumatol Port ; 35(1): 95-8, 2010.
Artículo en Inglés | MEDLINE | ID: mdl-20505635

RESUMEN

The authors present the revised version of the Portuguese Society of Rheumatology (SPR) guidelines for the treatment of rheumatoid arthritis (RA) with biological therapies. In these guidelines the criteria for introduction and maintenance of biological agents are discussed as well as the contraindications and procedures in the case of non-responders. Biological treatment should be considered in RA patients with a disease activity score 28 (DAS 28) superior to 3.2 despite treatment with 20mg/week of methotrexate (MTX) for at least 3 months or, if such treatment is not possible, after 6 months of other conventional disease modifying drug or combination therapy. A DAS 28 score between 2.6 and 3.2 with a significant functional or radiological deterioration under treatment with conventional regimens could also constitute an indication for biological treatment. The treatment goal should be remission or, if that is not achievable, at least a low disease activity, characterized by a DAS28 lower than 3.2, without significative functional or radiological worsening. The response criteria, at the end of the first 3 months of treatment, are a decrease of 0.6 in the DAS28 score. After 6 months of treatment response criteria is defined as a decrease of more than 1.2 in the DAS28 score. Non-responders, in accordance to the Rheumatologist's clinical opinion, should try a switch to another biological agent (tumour necrosis factor antagonist, abatacept, rituximab or tocilizumab).


Asunto(s)
Artritis Reumatoide/tratamiento farmacológico , Terapia Biológica , Humanos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA